4basebio Plc Joint Development Agreement with Heqet Therapeutics

 
TIDM4BB 
 
27 April 2022 
 
                                 4basebio PLC 
 
                  ("4basebio", the "Company" or the "Group") 
 
              Joint Development Agreement with Heqet Therapeutics 
    for development of a non-viral vector therapy for cardiac regeneration 
 
4basebio PLC (AIM: 4BB), the life sciences group focused on exploiting 
intellectual property in the field of cell and gene therapies and DNA and mRNA 
vaccines, is pleased to announce a Joint Development Agreement ("JDA") with 
Heqet Therapeutics S.r.l. ("Heqet").  This JDA is focussed on the development 
of a non-viral vector, incorporating a proprietary Heqet payload for 
cardiomyocyte regeneration and treatment of myocardial infarction more broadly. 
 
Heqet recently closed an ?8m financing round to progress its development 
programmes. It is using its proprietary intellectual property to develop 
therapies which enable heart regeneration and renewal, thereby avoiding scar 
formation on the heart post myocardial infarction. Such scarring can eventually 
lead to cardiac dysfunction and failure, despite improvements in medical 
interventions. 
 
Under the JDA, the companies will evaluate the use of 4basebio's HermesT 
non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte 
regeneration.  The successful outcome of this project may lead to the 
proof-of-concept development of a therapy enabling heart regeneration post 
infarction. 
 
Dr Heikki Lanckriet, CEO and CSO for 4basebio, said: "We are delighted to be 
working with Heqet on this novel therapy approach for heart repair following 
myocardial infarction. This further demonstrates the flexible application of 
our HermesT targeted delivery technology within the cell and gene therapy 
markets." 
 
Dr Marta Antonucci, CEO of Heqet, said: "We are delighted to be working with 
4basebio in developing a vector targeting cardiomyocyte regeneration. 4basebio 
and Heqet bring complementary expertise and technologies to this exciting 
program." 
 
For further enquiries, please contact: 
 
4basebio PLC                                                     [phone] 
7943 
 
Heikki Lanckriet 
 
Nominated Adviser                                           [phone] 
 
Cairn Financial Advisers LLP 
 
Jo Tuner / Sandy Jamieson 
 
Broker                                                                +44 (0)20 
7220 0500 
 
finnCap Ltd 
 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe 
 
Notes to Editors 
 
About 4basebio 
 
4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic 
DNA for cell and gene therapies and DNA vaccines and providing solutions for 
effective and safe delivery of these DNA based products to patients. It is the 
intention of the Company to become a market leader in the manufacture and 
supply of high purity, synthetic DNA for research, therapeutic and 
pharmacological use and develop non-viral vectors for the efficient delivery of 
payloads. The immediate objectives of 4basebio are to continue the validation 
of its DNA products and HermesT technology and commence revenue generation 
during 2022. 4basebio also continues to advance its collaborations to 
facilitate the functional validation of its DNA based products and cell and 
gene delivery solutions. 
 
About Heqet 
 
Heqet Therapeutics is an early-stage biotech company focussed on developing 
novel RNAi therapeutics to reverse the damage created by ischemic heart 
disease, the leading cause of death worldwide. The company is using the 
proceeds from its successful financing round to execute its pre-clinical plan 
and advance its programs towards clinical application. 
 
Forward-looking statements 
 
This announcement may contain certain statements about the future outlook for 
the 4basebio.  Although the directors believe their expectations are based on 
reasonable assumptions, any statements about future outlook may be influenced 
by factors that could cause actual outcomes and results to be materially 
different. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

April 27, 2022 02:00 ET (06:00 GMT)